Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5 also known as Survivin is a protein encoded by the BIRC5 gene. It has dual roles in promoting cell proliferation and preventing apoptosis. It acts as an important regulator of the localization of this complex directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. It counteracts a default induction of apoptosis in G2/M phase. It plays a role in neoplasia.
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) pipeline Target constitutes close to 21 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 5, 9 and 2 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 2 and 3 molecules, respectively. Report covers products from therapy areas Oncology and Immunology which include indications Prostate Cancer, Pancreatic Cancer, Bladder Cancer, Melanoma, Autoimmune Disorders, Bone Metastasis, Colorectal Cancer, Ovarian Cancer, Breast Cancer, Colon Carcinoma, Diffuse Large B-Cell Lymphoma, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Kidney Cancer (Renal Cell Cancer), Lymphoma, Malignant Mesothelioma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Lung Cancer, Multiple Myeloma (Kahler Disease), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Small Cell Lung Cancer, Peritoneal Cancer, Recurrent Glioblastoma Multiforme (GBM) and Solid Tumor.
The latest report Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H1 2018, outlays comprehensive information on the Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)
- The report reviews Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H1 2018
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Overview
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Companies Involved in Therapeutics Development
Biomics Biotechnologies Co Ltd
Bioneer Corp
Boehringer Ingelheim GmbH
Immunovaccine Inc
MimiVax LLC
Optimum Therapeutics LLC
Polyplus-Transfection SA
Stemline Therapeutics Inc
tella Inc
Vaxeal Holding SA
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Drug Profiles
Antibody to Target Survivin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Inhibit Survivin and Bcl-2 for Bladder Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Inhibit Survivin and Cyclin B1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Inhibit Survivin for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer and Bladder Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGA-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-1361849 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BKM-1644 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BKM-1740 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPX-Survivac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FL-118 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Survivin for Oncology and Autoimmune Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MX-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SVX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UC-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Colon Carcinoma and Lymphoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Survivin for Autoimmune Diseases, Glioblastoma Multiforme and Multiple Myeloma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Survivin for Breast Cancer and Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Dormant Products
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Discontinued Products
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Product Development Milestones
Featured News & Press Releases
Dec 05, 2017: Immunovaccine Announces Positive Clinical Data from Its Collaborative Combination Immunotherapy Trial in Advanced Ovarian Cancer
Dec 05, 2017: Immunovaccine to Hold Webcast and Conference Call to Discuss Clinical Data From Its Collaborative Combination Immunotherapy Trial in Advanced Ovarian Cancer
Nov 16, 2017: Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO)
Nov 08, 2017: Immunovaccine Announces Regulatory Clearance for Phase 2 Clinical Trial Evaluating DPX-Survivac in Combination with Merck's Checkpoint Inhibitor Pembrolizumab in DLBCL
Aug 07, 2017: FDA Awards Orphan Status to Brain Cancer Vaccine Developed at Roswell Park Cancer Institute
May 16, 2017: Immunovaccines Lead Immuno-Oncology Candidate to Enter Investigator-Sponsored Phase 2 Clinical Trial in DLBCL in Combination with Approved Anti-PD-1 Drug
Apr 11, 2017: Princess Margaret Cancer Center Receives Health Canada Clearance to Begin Investigator-Sponsored Phase 2 Ovarian Cancer Study Evaluating Immunovaccine's DPX-Survivac with Merck's Pembrolizumab
Mar 29, 2017: Immunovaccine Announces Positive Interim Clinical Data from Ovarian Cancer Study of DPX-Survivac in Combination with Epacadostat
Feb 21, 2017: Stemline Therapeutics Provides Update on SL-701
Feb 06, 2017: Immunovaccines Lead Immuno-Oncology Candidate to Enter Investigator-Sponsored Phase 2 Clinical Trial in Ovarian Cancer in Combination With Approved Anti-PD-1 Drug
Nov 22, 2016: The European Medicines Agency Grants Orphan Drug Designation Status to Immunovaccine's DPX-Survivac in Ovarian Cancer
Nov 21, 2016: Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 21st Annual Meeting of the Society of Neuro-Oncology (SNO)
Sep 08, 2016: Immunovaccine Announces Dosing of First Patient in Phase 1b Clinical Trial for DPX-Survivac in Combination with Incyte's IDO1 Enzyme Inhibitor Epacadostat
Aug 25, 2016: Immunovaccine Announces Additional Positive Topline Results from Phase 1/1b Clinical Trial Program with DPX-Survivac in Ovarian Cancer
May 31, 2016: Clinical Trial Will Explore First-Time Use of SurVaxM Vaccine in Combination with REVLIMID® to Treat Rare Blood Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Biomics Biotechnologies Co Ltd, H1 2018
Pipeline by Bioneer Corp, H1 2018
Pipeline by Boehringer Ingelheim GmbH, H1 2018
Pipeline by Immunovaccine Inc, H1 2018
Pipeline by MimiVax LLC, H1 2018
Pipeline by Optimum Therapeutics LLC, H1 2018
Pipeline by Polyplus-Transfection SA, H1 2018
Pipeline by Stemline Therapeutics Inc, H1 2018
Pipeline by tella Inc, H1 2018
Pipeline by Vaxeal Holding SA, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Dormant Products, H1 2018 (Contd..2), H1 2018
Discontinued Products, H1 2018
List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
Global Cytokine Inhibitor Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 85
The global Cytokine Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
The development prospects of cytokine inhibitors are very broad, and these drugs have many medical applications and researches. Cytokine inhibitors can reduce The activity of cytokines, thereby inhibiting their role in immune responses and reducing The activation of immune cells and The occurrence o......
Global Microbial Growth Media Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 93
Microbial Growth Media is a nutrient component required by microorganisms, containing a variety of trace elements and trace elements, such as copper, iron, zinc, cobalt, manganese, etc.
The global Microbial Growth Media market was valued at US$ 8007 million in 2023 and is anticipated to reach US$ 11530 million by 2030, witnessing a CAGR of 5.3% during The forecast period 2024-2030.
The market for microbial growth media is essential in microbiology and biotechnology rese......
Global Protein Biochip Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 92
Protein Biochip is a small Protein array used to quickly detect a large number of unknown proteins. It works in a similar way to a DNA chip. First, a large number of known proteins (such as monoclonal antibodies) are placed on a small substrate and then exposed to and reacted with The unknown protein sample. Due to The specific binding between The antigen and The antibody, it can finally be detected by means of laser.
The global Protein Biochip market was valued at US$ 145 million i......
Global Isothermal Nucleic Acid Amplification Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 103
Isothermal nucleic acid amplification is referred to isothermal nucleic acid amplification technology. And in this report, we get The statistics on reagents used in isothermal nucleic acid amplification technology. Nucleic acid isothermal amplification is a newer technique that amplifies DNA or RNA specific fragment from few copies to billion-fold copies under a one temperature condition, unlike PCR amplification that needs at least 30-35 thermal cycles to accomplish The reaction.
T......
Global Microfluidics Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 134
According to our LPI (LP Information) latest study, the global Microfluidics market size was valued at US$ 3118.7 million in 2023. With growing demand in downstream market, the Microfluidics is forecast to a readjusted size of US$ 7707.1 million by 2030 with a CAGR of 13.8% during review period.
The research report highlights the growth potential of the global Microfluidics market. Microfluidics are expected to show stable growth in the future market. However, product differentiation, re......
Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 122
According to our LPI (LP Information) latest study, the global Isothermal Nucleic Acid Amplification Technology (INAAT) market size was valued at US$ 6141.3 million in 2023. With growing demand in downstream market, the Isothermal Nucleic Acid Amplification Technology (INAAT) is forecast to a readjusted size of US$ 11250 million by 2030 with a CAGR of 9.0% during review period.
The research report highlights the growth potential of the global Isothermal Nucleic Acid Amplification Technol......
Global Cytokines Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 119
According to our LPI (LP Information) latest study, the global Cytokines market size was valued at US$ 203730 million in 2023. With growing demand in downstream market, the Cytokines is forecast to a readjusted size of US$ 611910 million by 2030 with a CAGR of 17.0% during review period.
The research report highlights the growth potential of the global Cytokines market. Cytokines are expected to show stable growth in the future market. However, product differentiation, reducing costs, an......
Global Western Blot Imagers Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 94
According to our LPI (LP Information) latest study, the global Western Blot Imagers market size was valued at US$ 406 million in 2023. With growing demand in downstream market, the Western Blot Imagers is forecast to a readjusted size of US$ 578.4 million by 2030 with a CAGR of 5.2% during review period.
The research report highlights the growth potential of the global Western Blot Imagers market. Western Blot Imagers are expected to show stable growth in the future market. However, prod......
Global Procalcitonin Antibody Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 125
According to our LPI (LP Information) latest study, the global Procalcitonin Antibody market size was valued at US$ million in 2023. With growing demand in downstream market, the Procalcitonin Antibody is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Procalcitonin Antibody market. Procalcitonin Antibody are expected to show stable growth in the future market. However, product di......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
